TABLE 5.
Toxicities at least possibly related to treatment. Number of patients (%); n = 42 a
| Event | Any grade | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| Any adverse event | 42 (100) | 41 (98) | 39 (93) | 41 (98) | 14 (33) |
| Neutrophil count decreased | 38 (90) | 14 (33) | 29 (69) | 27 (64) | 13 (31) |
| Anemia | 38 (90) | 16 (38) | 34 (81) | 22 (52) | 0 |
| Platelet count decreased | 33 (79) | 25 (60) | 27 (64) | 10 (24) | 5 (12) |
| Fatigue | 29 (69) | 25 (60) | 12 (29) | 6 (14) | 0 |
| Nausea | 22 (52) | 19 (45) | 7 (17) | 2 (5) | 0 |
| Diarrhea | 19 (45) | 15 (36) | 4 (10) | 3 (7) | 0 |
| Lymphocyte count decreased | 17 (40) | 12 (29) | 12 (29) | 9 (21) | 0 |
| Peripheral neuropathy | 12 (29) | 12 (29) | 3 (7) | 0 | 0 |
| Vomiting | 11 (26) | 8 (19) | 2 (5) | 2 (5) | 0 |
| Alopecia | 11 (26) | 6 (14) | 5 (12) | 0 | 0 |
| Anorexia | 10 (24) | 8 (19) | 3 (7) | 1 (2) | 0 |
| Constipation | 9 (21) | 8 (19) | 1 (2) | 0 | 0 |
| Hypophosphatemia | 8 (19) | 2 (5) | 6 (14) | 2 (5) | 0 |
| Mucositis | 8 (19) | 7 (17) | 2 (5) | 0 | 0 |
| Myalgias | 7 (17) | 6 (14) | 1 (2) | 1 (2) | 0 |
| Abdominal pain | 6 (14) | 4 (10) | 1 (2) | 2 (5) | 0 |
| Hypomagnesemia | 6 (14) | 4 (10) | 2 (5) | 1 (2) | 0 |
| Dizziness | 6 (14) | 6 (14) | 0 | 0 | 0 |
| Rash | 6 (14) | 6 (14) | 0 | 0 | 0 |
| Hypertension | 5 (12) | 0 | 4 (10) | 1 (2) | 0 |
| ALT increased | 5 (12) | 3 (7) | 2 (5) | 0 | 0 |
| Dysgeusia | 5 (12) | 3 (7) | 2 (5) | 0 | 0 |
| Dyspepsia | 5 (12) | 3 (7) | 2 (5) | 0 | 0 |
| Headache | 5 (12) | 5 (12) | 0 | 0 | 0 |
| Alkaline phosphatase increased | 4 (10) | 3 (7) | 1 (2) | 0 | 0 |
| Dyspnea | 4 (10) | 3 (7) | 1 (2) | 0 | 0 |
| Weight loss | 4 (10) | 4 (10) | 2 (5) | 0 | 0 |
| Dehydration | 4 (10) | 1 (2) | 3 (7) | 0 | 0 |
| Hypoalbuminemia | 4 (10) | 1 (2) | 3 (7) | 0 | 0 |
| Sinus tachycardia | 4 (10) | 4 (10) | 0 | 0 | 0 |
a
One patient in schedule B who did not receive any study medication due to determination of ineligibility post‐registration is not included in this analysis.